| Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 … TA Hope, M Eiber, WR Armstrong, R Juarez, V Murthy, C Lawhn-Heath, ... JAMA oncology 7 (11), 1635-1642, 2021 | 173 | 2021 |
| Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study A Gafita, J Calais, TR Grogan, B Hadaschik, H Wang, M Weber, S Sandhu, ... The Lancet Oncology 22 (8), 1115-1125, 2021 | 146 | 2021 |
| Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study A Gafita, I Rauscher, M Weber, B Hadaschik, H Wang, WR Armstrong, ... Journal of Nuclear Medicine 63 (11), 1651-1658, 2022 | 76 | 2022 |
| Head-to-head comparison of 68Ga-PSMA-11 PET/CT and mpMRI with a histopathology gold standard in the detection, intraprostatic localization, and determination of local extension … I Sonni, ER Felker, AT Lenis, AE Sisk, S Bahri, M Allen-Auerbach, ... Journal of Nuclear Medicine 63 (6), 847-854, 2022 | 56 | 2022 |
| Total-body 68Ga-PSMA-11 PET/CT for bone metastasis detection in prostate cancer patients: Potential impact on bone scan guidelines KL Pomykala, J Czernin, TR Grogan, WR Armstrong, J Williams, J Calais Journal of Nuclear Medicine 61 (3), 405-411, 2020 | 52 | 2020 |
| Tumor sink effect in 68Ga-PSMA-11 PET: myth or reality? A Gafita, H Wang, A Robertson, WR Armstrong, R Zaum, M Weber, ... Journal of Nuclear Medicine 63 (2), 226-232, 2022 | 51 | 2022 |
| Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria A Gafita, I Rauscher, WP Fendler, V Murthy, W Hui, WR Armstrong, ... European Journal of Nuclear Medicine and Molecular Imaging 49 (12), 4271-4281, 2022 | 46 | 2022 |
| Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion IA Elliott, AM Dann, S Xu, SS Kim, ER Abt, W Kim, S Poddar, A Moore, ... Proceedings of the National Academy of Sciences 116 (14), 6842-6847, 2019 | 45 | 2019 |
| Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the … J Calais, A Gafita, M Eiber, WR Armstrong, J Gartmann, P Thin, K Nguyen, ... Journal of Nuclear Medicine 62 (10), 1440-1446, 2021 | 42 | 2021 |
| Update from PSMA-SRT trial NCT03582774: a randomized phase 3 imaging trial of prostate-specific membrane antigen positron emission tomography for salvage radiation therapy for … J Calais, WR Armstrong, AU Kishan, KM Booker, TA Hope, WP Fendler, ... European urology focus 7 (2), 238, 2021 | 33 | 2021 |
| A comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: results from a prospective multicenter study on 2,005 patients M Abghari-Gerst, WR Armstrong, K Nguyen, J Calais, J Czernin, D Lin, ... Journal of Nuclear Medicine 63 (4), 567-572, 2022 | 26 | 2022 |
| Identifying the best candidates for prostate-specific membrane antigen positron emission tomography/computed tomography as the primary staging approach among men with high-risk … TM Ma, A Gafita, D Shabsovich, J Juarez, TR Grogan, P Thin, ... European urology oncology 5 (1), 100-103, 2022 | 21 | 2022 |
| Accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase III imaging study. TA Hope, WR Armstrong, V Murthy, C Lawhn Heath, S Behr, F Barbato, ... Journal of Clinical Oncology 38 (15_suppl), 5502-5502, 2020 | 21 | 2020 |
| PSMA PET validates higher rates of metastatic disease for European Association of Urology Biochemical Recurrence Risk Groups: An international multicenter study J Ferdinandus, WP Fendler, A Farolfi, S Washington, O Mohamad, ... Journal of Nuclear Medicine 63 (1), 76-80, 2022 | 18 | 2022 |
| Safety of PSMA-targeted molecular radioligand therapy with 177Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC (NCT03042312) J Calais, J Czernin, P Thin, J Gartmann, K Nguyen, WR Armstrong, ... Journal of Nuclear Medicine 62 (10), 1447-1456, 2021 | 15 | 2021 |
| The impact of monosodium glutamate on 68Ga-PSMA-11 biodistribution in men with prostate cancer: A prospective randomized, controlled imaging study WR Armstrong, A Gafita, S Zhu, P Thin, K Nguyen, R Alano, S Lira, ... Journal of Nuclear Medicine 62 (9), 1244-1251, 2021 | 12 | 2021 |
| Head-to-head comparison of 68Ga-PSMA-11 PET/CT and mpMRI in the detection, intra-prostatic localization, and local extension of primary prostate cancer: A single-center imaging … I Sonni, E Felker, AT Lenis, AE Sisk, S Bahri, MS Auerbach, ... Journal of Clinical Oncology 39 (6_suppl), 193-193, 2021 | 7 | 2021 |
| Overall survival after 177Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer: Post-hoc analysis of a prospective … J Calais, J Gartmann, WR Armstrong, P Thin, K Nguyen, V Lok, L Gosa, ... Journal of Clinical Oncology 38 (15_suppl), 5549-5549, 2020 | 5 | 2020 |
| Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial L Djaïleb, WR Armstrong, D Thompson, A Gafita, A Farolfi, A Rajagopal, ... European Urology 84 (6), 588-596, 2023 | 4 | 2023 |
| 18F-FDG PET/CT imaging biomarkers for early and late evaluation of response to first-line chemotherapy in patients with pancreatic ductal adenocarcinoma MR Benz, WR Armstrong, F Ceci, G Polverari, TR Donahue, ZA Wainberg, ... Journal of Nuclear Medicine 63 (2), 199-204, 2022 | 4 | 2022 |
